Leila Farooq

XRP Experiences Significant Uptick Amidst Geopolitical and Economic Factors

Cryptocurrency Sees Elevated Trading Volumes and Price Gains Early in 2026

XRP, the digital currency token, has recorded notable price gains in early 2026, driven by heightened investor appetite for risk and geopolitical even...

Palomar (PLMR): Buy on 4Q Outperformance Probability and M&A-Driven Growth

Solid sequential revenue/earnings ramp, cash flow strength and two strategic surety deals make a tactical long—buy on weakness, manage acquisition execution risk

Palomar has shown accelerating top-line and EPS across 2025 quarters, strong operating cash flow, and is actively supplementing organic growth with ta...

Bank of America Elevates Duolingo Stock, Emphasizing Entertainment Value and Growth Prospects

Analysts underscore Duolingo’s dual role in education and casual gaming, highlighting high retention and monetization metrics

Bank of America Securities upgraded Duolingo, Inc. (NASDAQ: DUOL) from Neutral to Buy, emphasizing the company's broader potential as both a language ...

Tenax Therapeutics: Lower Phase-3 Variance Has Tilted the Odds — A Long Trade for an Asymmetric Reprice

Clinical noise down, optionality intact — buy a clinical-stage specialty pharma with a clean balance sheet and a lot to gain if levosimendan de-risks.

Tenax (TENX) is a small specialty pharma with North American rights to levosimendan. Recent clinical progress and a materially stronger balance sheet ...

Micron Upgrade: Memory Supercycle Meets Clean Balance Sheet - Trade the Run

Strong Q1 results, hefty margins, and tightening supply make MU a tactical long - structured entry, stops and targets included.

Micron reported a blowout quarter (Q1 FY2026) with $13.64B revenue and $4.60 diluted EPS, returning to cyclical high margins. Inventory discipline, $8...

Palantir Is Still Worth Buying — Buy the Dip, Manage the Multiple

Strong quarterly cadence, cash generation, and AI demand justify a tactical long setup — but valuation and contract concentration require tight risk control.

Palantir (PLTR) reported accelerating revenue and profit across the first three quarters of FY2025, is cash-generative, and sits squarely in the enter...

Incyte Reports Positive Phase 3 Trial Data for Tafasitamab Combination in First-Line DLBCL Treatment

Phase 3 frontMIND study shows improved progression-free and event-free survival with tafasitamab plus lenalidomide added to R-CHOP regimen

Incyte Corporation unveiled encouraging results from the Phase 3 frontMIND clinical trial evaluating the addition of tafasitamab and lenalidomide to t...

Expedia: Strong Quarterly Earnings, Cheap Multiple - Buy the Dip with Defined Risk

Q3 2025 showed outsized profitability; market cap (~$37.4B) implies a sub-10x multiple on run-rate earnings — tactical long.

Expedia reported a $964M net profit in Q3 2025 (diluted EPS $7.33) and operating income of $1.036B, demonstrating that its core OTA businesses still g...

Momentum Indicators Suggest Potential Downturns for Leading Industrials Stocks in Early January 2026

Elevated RSI levels in top industrials signal caution for investors emphasizing momentum in their trading strategies

As the new year unfolds, key stocks within the industrials sector are exhibiting signs of elevated momentum that could presage price corrections. Util...

Wall Street's Top Analyst Stock Picks Highlight Potential Gains in Tech and Finance Sectors

Experts Identify Key Stocks with Robust Upside Potential for 2026 Amid Strong Market Performance

U.S. equity markets displayed notable strength with major indexes ending the week higher. Analysts with high accuracy ratings have provided fresh stoc...